Altasciences Wins 2025 CDMO Leadership Award for Small Molecule Dosage Forms
Altasciences, a recognized leader in contract development and manufacturing (CDMO) services, has been honored with the 2025 CDMO Leadership Award in the Small Molecule Dosage Form–North America category. This achievement marks another milestone in the company’s longstanding commitment to advancing drug development through innovation and collaboration with leading pharmaceutical and biotech companies.
Marie-Hélène Raigneau, Co-Chief Operating Officer at Altasciences, expressed her appreciation for the award, stating, “This recognition reflects our CDMO team’s unwavering dedication and expertise, as well as our unrelenting commitment to advancing drug development in collaboration with leading pharmaceutical and biotech innovators. We are grateful for the opportunity to partner with esteemed sponsors from around the globe, providing them with integrated solutions that not only support groundbreaking therapeutic progress but also contribute meaningfully to getting those therapies to those who need them, faster.”
Altasciences operates a state-of-the-art CDMO facility equipped with Grade C cleanrooms, R&D and analytical laboratories, ICH stability chambers, and a cGMP warehouse. This FDA-inspected site supports drug development at all stages, from discovery to commercialization, offering formulation development, manufacturing, and analytical testing services. The company has experience handling nearly every available pharmaceutical dosage form, including tablets, liquid- and powder-filled capsules, over-encapsulated capsules, nanomilled suspensions, creams, gels, powders, and terminally sterilized injectables.
The CDMO Leadership Awards, presented annually by Outsourced Pharma, recognize the top-performing contract development and manufacturing organizations based on comprehensive industry research and sponsor feedback. Louis Garguilo, Chief Editor at Outsourced Pharma, highlighted the significance of the awards, stating, “We are thrilled to introduce our 2025 CDMO Leadership Awards winners to the outsourcing community and honored to offer such an important tool for drug sponsors in selecting their best-fit partner to help bring life-saving therapies to market. The new categories and enhanced scoring methodology that went into this year’s appraisal bring an improved experience for drug sponsors using the resource, as well as an ever-so-coveted distinction for the CDMOs.”
Altasciences’ integrated service model enables seamless transitions between preclinical and clinical phases, expediting the delivery of safe and effective therapeutics. By leveraging in-house analytical testing and environmental monitoring, the company ensures batch consistency and regulatory compliance. Their ability to provide end-to-end CDMO solutions, combined with a focus on accelerating drug development timelines, positions Altasciences as a trusted partner in the pharmaceutical and biotech industries.
As the demand for small molecule drug development continues to rise, Altasciences remains dedicated to pushing the boundaries of innovation in formulation and manufacturing. Their comprehensive expertise and state-of-the-art infrastructure enable them to provide customized solutions tailored to the specific needs of their clients, further solidifying their role as a key player in the CDMO sector.
The importance of CDMO services in the pharmaceutical industry continues to grow, as more companies seek reliable partners to manage the complex processes of drug development. Altasciences stands out by offering a comprehensive suite of services that not only streamline drug manufacturing but also ensure compliance with the latest regulatory requirements. Their extensive experience allows them to anticipate potential challenges and proactively implement solutions that minimize delays and optimize the path to commercialization.
In addition to their expertise in small molecule dosage forms, Altasciences is continually expanding its capabilities to support novel therapeutic modalities. The company is investing in advanced manufacturing technologies and analytical tools to enhance precision, efficiency, and scalability in drug production. This forward-thinking approach ensures that Altasciences remains at the forefront of pharmaceutical innovation, ready to meet the evolving needs of the industry.
Altasciences’ commitment to quality and efficiency is also reflected in their collaborative approach to working with clients. By fostering strong partnerships and maintaining open communication, they provide tailored solutions that align with each client’s strategic goals. This level of flexibility and responsiveness has made Altasciences a preferred CDMO partner for both emerging biotech firms and established pharmaceutical companies looking to bring new therapies to market efficiently.
The recognition from the CDMO Leadership Awards underscores Altasciences’ ability to drive innovation and excellence in drug development. As the company continues to grow, they remain focused on expanding their service offerings, enhancing their technological capabilities, and strengthening their global presence. These efforts will further position Altasciences as a leader in the contract development and manufacturing space, ensuring that they remain a key contributor to the advancement of pharmaceutical science.
With this latest accolade, Altasciences reaffirms its position as a leader in the field, continuously striving to enhance drug development processes and bring transformative therapies to patients worldwide. The company looks forward to expanding its capabilities and forging new partnerships to further its mission of accelerating therapeutic advancements through high-quality CDMO services. By staying ahead of industry trends and investing in new technologies, Altasciences is well-equipped to support the next generation of pharmaceutical breakthroughs, ultimately improving patient outcomes and shaping the future of medicine
Altasciences, a recognized leader in contract development and manufacturing (CDMO) services, has been honored with the 2025 CDMO Leadership Award in the Small Molecule Dosage Form–North America category. This achievement marks another milestone in the company’s longstanding commitment to advancing drug development through innovation and collaboration with leading pharmaceutical and biotech companies.
Marie-Hélène Raigneau, Co-Chief Operating Officer at Altasciences, expressed her appreciation for the award, stating, “This recognition reflects our CDMO team’s unwavering dedication and expertise, as well as our unrelenting commitment to advancing drug development in collaboration with leading pharmaceutical and biotech innovators. We are grateful for the opportunity to partner with esteemed sponsors from around the globe, providing them with integrated solutions that not only support groundbreaking therapeutic progress but also contribute meaningfully to getting those therapies to those who need them, faster.”
Altasciences operates a state-of-the-art CDMO facility equipped with Grade C cleanrooms, R&D and analytical laboratories, ICH stability chambers, and a cGMP warehouse. This FDA-inspected site supports drug development at all stages, from discovery to commercialization, offering formulation development, manufacturing, and analytical testing services. The company has experience handling nearly every available pharmaceutical dosage form, including tablets, liquid- and powder-filled capsules, over-encapsulated capsules, nanomilled suspensions, creams, gels, powders, and terminally sterilized injectables.
The CDMO Leadership Awards, presented annually by Outsourced Pharma, recognize the top-performing contract development and manufacturing organizations based on comprehensive industry research and sponsor feedback. Louis Garguilo, Chief Editor at Outsourced Pharma, highlighted the significance of the awards, stating, “We are thrilled to introduce our 2025 CDMO Leadership Awards winners to the outsourcing community and honored to offer such an important tool for drug sponsors in selecting their best-fit partner to help bring life-saving therapies to market. The new categories and enhanced scoring methodology that went into this year’s appraisal bring an improved experience for drug sponsors using the resource, as well as an ever-so-coveted distinction for the CDMOs.”
Altasciences’ integrated service model enables seamless transitions between preclinical and clinical phases, expediting the delivery of safe and effective therapeutics. By leveraging in-house analytical testing and environmental monitoring, the company ensures batch consistency and regulatory compliance. Their ability to provide end-to-end CDMO solutions, combined with a focus on accelerating drug development timelines, positions Altasciences as a trusted partner in the pharmaceutical and biotech industries.
As the demand for small molecule drug development continues to rise, Altasciences remains dedicated to pushing the boundaries of innovation in formulation and manufacturing. Their comprehensive expertise and state-of-the-art infrastructure enable them to provide customized solutions tailored to the specific needs of their clients, further solidifying their role as a key player in the CDMO sector.
The importance of CDMO services in the pharmaceutical industry continues to grow, as more companies seek reliable partners to manage the complex processes of drug development. Altasciences stands out by offering a comprehensive suite of services that not only streamline drug manufacturing but also ensure compliance with the latest regulatory requirements. Their extensive experience allows them to anticipate potential challenges and proactively implement solutions that minimize delays and optimize the path to commercialization.
In addition to their expertise in small molecule dosage forms, Altasciences is continually expanding its capabilities to support novel therapeutic modalities. The company is investing in advanced manufacturing technologies and analytical tools to enhance precision, efficiency, and scalability in drug production. This forward-thinking approach ensures that Altasciences remains at the forefront of pharmaceutical innovation, ready to meet the evolving needs of the industry.
Altasciences’ commitment to quality and efficiency is also reflected in their collaborative approach to working with clients. By fostering strong partnerships and maintaining open communication, they provide tailored solutions that align with each client’s strategic goals. This level of flexibility and responsiveness has made Altasciences a preferred CDMO partner for both emerging biotech firms and established pharmaceutical companies looking to bring new therapies to market efficiently.
The recognition from the CDMO Leadership Awards underscores Altasciences’ ability to drive innovation and excellence in drug development. As the company continues to grow, they remain focused on expanding their service offerings, enhancing their technological capabilities, and strengthening their global presence. These efforts will further position Altasciences as a leader in the contract development and manufacturing space, ensuring that they remain a key contributor to the advancement of pharmaceutical science.
With this latest accolade, Altasciences reaffirms its position as a leader in the field, continuously striving to enhance drug development processes and bring transformative therapies to patients worldwide. The company looks forward to expanding its capabilities and forging new partnerships to further its mission of accelerating therapeutic advancements through high-quality CDMO services. By staying ahead of industry trends and investing in new technologies, Altasciences is well-equipped to support the next generation of pharmaceutical breakthroughs, ultimately improving patient outcomes and shaping the future of medicine
About Altasciences
Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 30 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, research support, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster. To learn more about Altasciences, visit altasciences.com.
